---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-005504"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:55:02.249656+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Palatin to host KOL webinar on PL9643 Phase 3 dry eye data on May 8, 2023

## Summary
- Webinar to review positive PL9643 Phase 3 MELODY-1 Lead-In population data for moderate to severe dry eye disease.
- Final PL9643 Phase 3 MELODY-1 data expected in H2 2023; trial enrollment continuing.
- Webinar moderated by CEO Carl Spana; featuring KOLs Dr. Stouch, Mr. Ousler, and CMO Dr. Raizman.
- Company cites PL9643 positive effects on both signs and symptoms of dry eye disease.

## SEC filing metadata
- accession: 0001654954-23-005504
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495423005504/0001654954-23-005504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495423005504/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-005504
- JSON: https://secwatch.observer/filing/0001654954-23-005504.json
- Plain text: https://secwatch.observer/filing/0001654954-23-005504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.